Primary-source record
Decision-gradeTrial registry change
Cardiol Therapeutics expands Phase 3 MAVERIC trial of CardiolRx in recurrent pericarditis
Cardiol achieved its original 110-patient enrollment target in the Phase 3 MAVERIC trial ahead of the end-of-September 2026 guidance. Following a blinded review showing fewer-than-expected recurrences, the Steering Committee recommended expanding enrollment to up to 150 patients to preserve statistical power. Topline results are now guided for mid-2027.
Key facts
- Filed
- Sep 23, 2026, 06:00 PM
- Event
- Trial registry change
- Direction
- Neutral
- Company
CRDLCardiol Therapeutics- Asset
- CardiolRx
- Source
- Company press release
- Confidence
- Sourced
- original target
- 110 patients
- enrollment target
- up to 150 patients
Source excerpt
Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy News provided by Cardiol Therapeutics Inc. Sep 23, 2026, 06:00 ET Share this article Share to X Share this article Share to X Original 110-patient enrollment target achieved ahead of the Company's end-of-September guidance. The MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to capture sufficient events for a robust assessment of CardiolRx™'s potential to reduce recurrence risk. The recommendation follows a blinded review showing fewer-than-expected recurrences—an observation the Company views as encouraging. Topline results anticipated in mid-2027 following expanded enrollment and study completion. Existing capital expected to fund MAVERIC completion, with cash runway into Q1 2028. TORONTO , Sept. 23, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL ) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce enrollment progress and plans to expand MAVERIC, the Company's pivotal Phase III randomized, double-blind, placebo-controlled, multi-center trial evaluating CardiolRx™ for the redu